HBIO - קפיטליזציית שוק Harvard Bioscience

Harvard Bioscience relies on stable cash flows from the sale of laboratory systems while simultaneously expanding B2B deliveries of precision equipment in Europe and the US. This price chart on GURU.Markets reflects the price action of the asset, which has a market capitalization of 0.04. Long-term loyalty from the scientific community and a substantial patent portfolio ensure business resilience, creating high barriers to entry for new players in the sector.

The market value of Harvard Bioscience (HBIO) reflects the aggregate business valuation through the lens of demand for electrophysiology and biomedical research equipment. This metric is calculated as the product of the current share price and the total number of outstanding securities. By analyzing the capitalization dynamics of the public company, an investor determines the actual scale of the issuer. The stability of this metric confirms the resilience of B2B sales for laboratory systems, allowing a distinction between short-term speculation and the fundamental growth of business value.